Table 1.
Characteristics of the included studies
| Study | Patients(male) | Year(mean ± sd) | Intervention | Disease course(mean ± sd) | HBOT Efficacy | The CEBM Levels of Evidence |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IG | CG | IG | CG | IG | CG | IG | CG | ||||||
| Chen 2012 | 16(13) | 30(15) | 68.375 ± NR | 68.867 ± NR | HBOT + RDT + RT | RDT + RT | 1.75 ± NR(day) | 1.7 ± NR(day) |
No difference (after 10 days) Beneficial (after 1 month) |
Ib | |||
| Chen 2018 | 25(10) | 25(11) | 61.3 ± 8.7 | 62.7 ± 12.5 | HBOT + APT | APT | NR | NR | Beneficial | IIb | |||
| Nighoghossian 1995 | 17(9) | 17(12) | 53 ± 3 | 54 ± 3 | HBOT + RDT + RT | SHBOT + RDT + RT | 19 ± 2.7(hour) | 18 ± 3.2(hour) | Possibly beneficial | Ib | |||
| Rusyniak 2003 | 17(12) | 16(10) | 75 ± NR | 68 ± NR | HBOT | SHBOT | NR | NR |
No difference and Possibly harmful |
Ib | |||
| Zhu 2022 | 55(40) | 45(30) | 63.12 ± 9.74 | 61.18 ± 8.31 | HBOT + NWM | NWM | NR | NR | Beneficial | IIb | |||
| -Imai 2006 | 19(10) | 19(12) | 74.9 ± 12.1 | 73.7 ± 10.6 | HBOT + IE + RDT | IE + RDT | 546 ± 856(min) | 668 ± 639(min) | Possibly beneficial | IIb | |||
| Zhao 2008 | 50(28) | 62(36) | 65.7 ± 12.9 | 68.2 ± 13.7 | HBOT + RDT + RT | RDT + RT | NR | NR | Beneficial | IIb | |||
| Dong 2023 | 40(27) | 40(25) | 67.25 ± 3.51 | 66.80 ± 3.65 | HBOT + NBP + OXR | NBP + OXR | 6.81 ± 2.43(day) | 7.10 ± 2.66(day) | Beneficial | IIb | |||
IG: interventional group;CG: controlled group; NR: not reported; RDT: routine drug treatment; RT: rehabilitation therapy; APT: anti-platelet therapy; SHBOT: sham HBOT; NWM: needle-warming moxibustion; IE: intravenous edaravone; NBP: butylphthalide; OXR: oxiracetam